TG-01 is under clinical development by Circio Holding and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TG-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TG-01 overview

TG-01 is under development for the treatment of multiple myeloma, pancreatic cancer, pancreatic ductal adenocarcinoma, non-small cell lung cancer (NSCLC) and unspecified indication. It is administered as an intradermal and subcutaneous injection. It consists of seven RAS-mutated peptides and the immune-stimulator molgramostim targeting RAS mutations. The neoantigen vaccine is based on oncogenic amino acid substitutions at position 12 or 13 in p21 RAS. It was also under development for treatment of resected adenocarcinoma of the pancreas as adjuvant therapy and cancer in combination with TG-02, CPI synergy and PD-1.

Circio Holding overview

Circio Holding(Circio), formerly Targovax, is a developer and commercialize of immunotherapies for the treatment of cancer patients. The company’s lead candidates include TG01, a peptide-based therapeutic anti-cancer vaccine under development for pancreatic cancer and ONCOS-102 is an adenovirus-based pipeline product for solid tumor indications. It also provides TG02 and ONCOS-200 for other cancer indications. Targovax develops immunotherapies based on treatment approaches harnessing the patient’s immune system to target cancer cells, which include a virus-based immunotherapy platform based on engineered oncolytic viruses for solid tumors; and a peptide-based immunotherapy platform for RAS-mutated cancers. The company has operations in Norway and Finland. Circio is headquartered in Oslo, Norway.

For a complete picture of TG-01’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.